However, the expression changes of SLC9A2 during the metastatic progression of tumors, as well as its influence on the metastatic potential of CRC and the effects of CRC liver metastases on immunotherapy, remain unexplored. This evidence concerns the gene SLC9A2 and colorectal carcinoma.